The 2023 American Society of Clinical Oncology (ASCO) annual meeting, held June 2 to 6 in Chicago, highlighted important advances in treatment across a broad spectrum of malignancies. Here, Editor-in-Chief Dr. William Gradishar reviews key trials in breast cancer.
Adjuvant Ribociclib in Early-Stage ER+/HER2− Breast Cancer
Researchers presented long-awaited disease-free survival results from a planned interim analysis of the NATALEE trial, which evaluated adjuvant therapy with the CDK4/6 inhibitor ribociclib in patients with high-risk ER+/HER2− early-stage breast cancer (abstract LBA500). This large, industry-funded, phase 3 trial randomized a broader population of patients than either the PALLAS (palbociclib) or monarchE (abemaciclib) adjuvan…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)